product name Divalproex Sodium
Description: Divalproex Sodium, consisting of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form, is a HDAC inhibitor, used in the treatment for epilepsy. Divalproex sodium enhances IM-induced cell growth inhibition, apoptosis and cell cycle arrest in K562-S and K562-G cells. Divalproex sodium enhances the inhibitory effects of IM on SIRT1 expression in K562-S and K562-G cells. Divalproex sodium enhances the effect of IM on apoptosis in K562-G cells partly through SIRT1.
References: Cancer Lett. 2015 Jan 28;356(2 Pt B):791-9.
310.41
Formula
C8H16O2.C8H15O2.Na
CAS No.
76584-70-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 62 mg/mL (199.7 mM)
Water: 62 mg/mL (199.7 mM)
Ethanol: 62 mg/mL (199.7 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19395880
| In Vitro |
In vitro activity: Divalproex sodium enhances IM-induced cell growth inhibition, apoptosis and cell cycle arrest in K562-S and K562-G cells. Divalproex sodium enhances the inhibitory effects of IM on SIRT1 expression in K562-S and K562-G cells. Divalproex sodium enhances the effect of IM on apoptosis in K562-G cells partly through SIRT1. Divalproex (500 mg/kg) significantly increases dopamine (DA) and acetylcholine (ACh) efflux in the rat hippocampus, and DA, but not ACh, efflux in the rat medial prefrontal cortex (mPFC), whereas a lower dose of Divalproex, 50 mg/kg, has no effect on DA or ACh in either region. Divalproex (50 mg/kg) combined with the atypical APDs Olanzapine (1.0 mg/kg) or Aripiprazole (0.3 mg/kg) significantly potentiates the effect of both antipsychotic drugs (APDs) on DA, but not ACh efflux in the HIP and mPFC. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Cancer Lett. 2015 Jan 28;356(2 Pt B):791-9. |
Related Posts
product name Divalproex Sodium
Description: Divalproex Sodium, consisting of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form, is a HDAC inhibitor, used in the treatment for epilepsy. Divalproex sodium enhances IM-induced cell growth inhibition, apoptosis and cell cycle arrest in K562-S and K562-G cells. Divalproex sodium enhances the inhibitory effects of IM on SIRT1 expression in K562-S and K562-G cells. Divalproex sodium enhances the effect of IM on apoptosis in K562-G cells partly through SIRT1.
References: Cancer Lett. 2015 Jan 28;356(2 Pt B):791-9.
310.41
Formula
C8H16O2.C8H15O2.Na
CAS No.
76584-70-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 62 mg/mL (199.7 mM)
Water: 62 mg/mL (199.7 mM)
Ethanol: 62 mg/mL (199.7 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19395880
| In Vitro |
In vitro activity: Divalproex sodium enhances IM-induced cell growth inhibition, apoptosis and cell cycle arrest in K562-S and K562-G cells. Divalproex sodium enhances the inhibitory effects of IM on SIRT1 expression in K562-S and K562-G cells. Divalproex sodium enhances the effect of IM on apoptosis in K562-G cells partly through SIRT1. Divalproex (500 mg/kg) significantly increases dopamine (DA) and acetylcholine (ACh) efflux in the rat hippocampus, and DA, but not ACh, efflux in the rat medial prefrontal cortex (mPFC), whereas a lower dose of Divalproex, 50 mg/kg, has no effect on DA or ACh in either region. Divalproex (50 mg/kg) combined with the atypical APDs Olanzapine (1.0 mg/kg) or Aripiprazole (0.3 mg/kg) significantly potentiates the effect of both antipsychotic drugs (APDs) on DA, but not ACh efflux in the HIP and mPFC. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Cancer Lett. 2015 Jan 28;356(2 Pt B):791-9. |